Adam, the “Dividend Sensei” and I sit down to do some Gilead stock research (GILD). Adam provides a fire hydrant blast of information and expectations regarding Gilead, including some thoughts on the possibility of Gilead being acquired.
(Press play button to listen or click here to download.)
Subscribe: iTunes | Android | RSS
I’d like to see more content like this!
If you’d like to jump ahead in the interview to the discussion on Gilead’s acquisition prospects, it begins around the 20 minute mark of the interview.
A quick overview:
- Gilead’s free cash flow prospects.
- Company’s track record, culture, R&D, manufacturing process, patent portfolio, and pipeline.
- Adam’s price targets for Gilead.
- Who might purchase Gilead and for how much.
- How he plans to respond if price falls any further.
- Much more…
Companies Mentioned: Pfizer (PFE), JNJ (JNJ), Merck (MRK), Amgen (AMGN), AstraZeneca (AZN), AbbVie (ABBV)
I hope you enjoy this interview.
Best,
Brian
Content You’ll Also Like
105 Aurelien Windenberger – When SolarCity Will Run Out of Money
104 Richard Berger – The Coming Bear and How to Prepare
103 Leo Nelissen – How to Use the ISM Index and Durable Goods Report
106 Dividend Sensei – Gilead Stock Research – Why You Should Buy Gilead Stock
